Back to News
Market Impact: 0.2
CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP® in the USA - first revenue expected summer 2027
Source: PR Newswire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
CHOSA Oncology AB agreed with a CLIA-certified laboratory to develop and validate Platin-DRP® as a laboratory-developed test for potential US commercialization. The company expects first revenues in summer; the article does not specify the year.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CHOSA0.55
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Snap shares fall over 10% on third-quarter earnings miss
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- Drone Attacks Spawn New Insurance Market in Baltics, Poland
- REA Group shares rally on strong Q1 revenue